Pharmaceutical Market Research and Forecasting by Xcelsior Analytics Inc.
02/12/2015

Xcelsior Analytics Inc. analyses pharmaceutical drugs classes, indications, therapy areas data into meaningful & useful information for business purposes.

Online PR News – 12-February-2015 – India – Xcelsior Analytics Inc. is a pharmaceutical market research and consulting firm that analyses raw data into meaningful and useful information for business purposes. We deliver strategically analyzed excel-based consulting grade interactive reports for drug classes, indications or diseases and therapeutic areas that represent business intelligence information. We bring a blend of scientific knowledge, market experience and analytical skills that distills pharmaceutical data, concepts and methods to deliver global operational insights, strategies and decision-making to healthcare companies across the world.

Global Market for Therapy Areas, Drug Classes and Indications / Diseases:
Global Marketed and Pipeline Drugs Analysis and Forecast - 2014 to 2024:
Excel-based interactive market research reports for the following Drug Classes and Indications / Diseases markets comprising epidemiology data, FDA approvals & patent expirations, market dynamics (drivers, unmet needs, barriers) along with market size and forecast of current marketed drugs and Phase 3 & NDA-filed pipeline drugs. These market research reports also covers geographic (regional) market segmentation, market share of key players, mapping of clinical trials (Preclinical to Phase 3) and profiling of major companies in these market.

Therapy Areas:
Autoimmunity, Cardiovascular and Metabolic Diseases, Dermatology, Diabetes, Infectious Diseases, Inflammation and Immunology, Neuroscience and CNS, Disorders, Oncology, Rare Diseases, Respiratory, Sexual Health, Vaccines

Indications / Diseases:
Acne, Allergic Rhinitis, Allergies, Alzheimer's Disease, Angina, Anxiety, Arthritis, Asthma, Attention Deficit Hyper Disorder (ADHD), Bipolar Disorder, Bronchitis, Cervical Cancer, Cholesterol, Colds & Flu, Constipation, COPD, Depression, Diabetes (Type 2), Diarrhea, Eczema, Erectile Dysfunction, Fibromyalgia, Gastrointestinal, GERD (Heartburn), Gout, Hayfever, Heart Disease, Hepatitis A, Hepatitis B, Hypertension, Hypothyroidism, Incontinence, Inflammatory Bowel Disease (IBD), Insomnia, Leukemia (Blood Cancer), Menopause, Men's Health,Mental Health, Migraine, Multiple Myeloma, Multiple Sclerosis, Myelodysplastic Syndrome, Non-Small Cell Lung Cancer, Osteoarthritis, Osteoporosis, Ovarian Cancer, Pain, Parkinson's Disease, Prostate Cancer, Psoriasis, Rheumatoid Arthritis, Schizophrenia, Seizures, Skin Cancer, Stroke, Urinary Tract Infections (UTI), Weight Loss, Women's Health

Drug Classes:
Analgesics, Anti-Acne, Anti-Anxiety Agents, Anti-Asthmatics, Anti-Bacterials, Antibiotics, Anti-Convulsants, Anti-Depressants, Anti-Diabetics, Anti-Emetics, Anti-Epileptics, Anti-Flatulents, Anti-Fungals, Anti-Hyperlipidemics, Anti-Hypertensives and ACE Inhibitors, Anti-Inflammatory Agents, Anti-Malarials, Anti-Migrane Agents, Anti-Psychotics, Anti-Rheumatics, Anti-Tumor Drugs, Anti-Ulcerants, Anti-Virals, Beta Blockers, Contraceptives, Corticosteroids, Diuretics, Endocrine and Metabolic Agents, Fertility Drugs, Hormones, Immunosuppressants, Monoclonal antibodies, Muscle Relaxants, Narcotic Analgesics (Pain Killers), Nasal Medications, NSAIDs, Ophthalmologic Agents, Orphan Drugs, Sedatives and Hypnotics, Topicals (Anesthetics, Antibiotics, Antiseptics and Hemostatic Agents)

Company Forecast:
Market size and forecast (from 2012 to 2024) for all the drugs of any of the companies listed below, comprising current marketed drugs and Phase 3 & NDA-filed pipeline drugs.
AbbVie, Amgen, Astellas, AstraZeneca, Baxter, Bayer. Biogen Idec. Boehringer Ingelheim. Bristol-Myers Squibb, Eisai, GlaxoSmithKline, Johnson & Johnson, Lilly, Merck & Co., Novartis, Novo Nordisk, Otsuka, Pfizer, Roche, Sanofi, Takeda

Make informed decisions through better market research and comprehensive and integrated forecasting

An interactive interface for graphical and tabular destination to any section of the Therapy Area, Drug Class or Indication / Disease market report.

Epidemiology:
Qualitative analysis of the epidemiology data (causes, signs, symptoms and currently available treatments) for Therapy Area, Drug Class or Indication / Disease along with worldwide prevalence data of major indications treated by Therapy Area, Drug Class or Indication / Disease (forecasted till 2024).

FDA Approvals and Patent Expirations:
Tabular representation of all the FDA approvals and expected patent expirations of marketed Therapy Area, Drug Class or Indication / Disease along with expected FDA approval dates of Phase 3 and NDA-filed pipeline.

Market Dynamics and Principal Unmet Needs:
Description of principal unmet needs in the Therapy Area, Drug Class or Indication / Disease market coupled with the top indicators that are driving and restraining the market growth.

Market Size and Forecast – Total Drugs and Marketed Drugs:
• Quantitative Analysis of total drugs market and top marketed Therapy Area, Drug Class or Indication / Disease (estimated market size and forecast in USD million) for the period 2014 to 2024.
• Qualitative Analysis (patent expiry effects, influence of pipeline drugs, patient and physician preference) for the current marketed drugs in the Therapy Area, Drug Class or Indication / Disease market.

Market Size and Forecast - Phase 3 and NDA-filed Pipeline Drugs:
• Quantitative Analysis of Phase 3 and NDA-filed pipeline Therapy Area, Drug Class or Indication / Disease (estimated market size and forecast in USD million) for the period 2014 to 2024.
• Qualitative Analysis of Phase 3 and NDA-filed pipeline drugs (expected physician prescribing pattern and patient preference, competition with current marketed drugs) for the Therapy Area, Drug Class or Indication / Disease market.

Market Size and Forecast – Market by Major Indications:
Quantitative and qualitative analysis of major indications treated by Therapy Area, Drug Class or Indication / Disease (estimated market size and forecast in USD million) for the period 2014 to 2024.

Market Size and Forecast - Marketed Drugs by Geographic Regions:
Quantitative and qualitative analysis of marketed drugs in the Therapy Area, Drug Class or Indication / Disease market (estimated market size and forecast in USD million) by geographic regions for the period 2014 to 2024.
• Developed Regions (North America and Europe)
• Developing Regions (Asia-Pacific, Latin America and Middle-East)
• Rest of the World (RoW)

Market Share Analysis - Key Players (2014 and 2024):
% value market share estimated and analyzed for top players of the Therapy Area, Drug Class or Indication / Disease market for the year 2014 and forecasted for the year 2024.

Clinical Trials Mapping:
Clinical Trials Mapping for the Therapy Area, Drug Class or Indication / Disease market:
• Phases Mapped:
• Discovery and Preclinical Phase
• Clinical Phase 1
• Clinical Phase 2
• Clinical Phase 3
• Data Points Covered:
• Number of clinical trials in each phase
• Number of “new or first-in-class” molecules, “me-too” drugs and “generic” drugs
• Number of companies and their comparative analysis

Company Profiles:
Top 5 companies (current marketed drugs) and Top 3 Companies (pipeline drugs) in the Therapy Area, Drug Class or Indication / Disease market profiled with following parameters (tabular representation):
• Financials (total revenue and specific market revenues)
• Business Overview
• Product Review
• Major Consolidations (mergers and acquisitions, joint ventures, partnerships and collaborations)

Company Forecast:
Global Marketed and Pipeline Drugs Analysis and Forecast - 2012 to 2024
Market size and forecast (from 2012 to 2024) for all the drugs of any of the companies listed below, comprising current marketed drugs and Phase 3 & NDA-filed pipeline drugs.
AbbVie, Amgen, Astellas, AstraZeneca, Baxter, Bayer. Biogen Idec. Boehringer Ingelheim. Bristol-Myers Squibb, Eisai, GlaxoSmithKline, Johnson & Johnson, Lilly, Merck & Co., Novartis, Novo Nordisk, Otsuka, Pfizer, Roche, Sanofi, Takeda.
Sources and Methodology

Tabular representation of principal secondary and primary sources utilized and description of the detailed methodology and assumptions adopted while estimating the Therapy Area, Drug Class or Indication / Disease market.

For further information on Table of Contents, Report Descriptions, Sample Pages and Promotional offers, visit us at http://www.xcelsioranalytics.com or send your requirements and/or questions by email: info @ xcelsioranalytics . com Alternatively, fill up the enquiry form or order form.